Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Hughes (Sheffield, United Kingdom), A. Swift (Sheffield, United Kingdom), F. Wilson (Stevenage, United Kingdom), M. Cogliano (Sheffield, United Kingdom), F. Alandejani (Sheffield, United Kingdom), A. Cahn (Stevenage, United Kingdom), L. Kendall (Stevenage, United Kingdom), D. Kiely (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom). Lung perfusion in pulmonary hypertension – results from the RESPIRE study. 1519

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary hypertension due to lung disease – Results from COMPERA Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Pulmonary function is associated with pulmonary artery systolic pressure in the general population: The Rotterdam study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 An epidemiological study of pulmonary arterial hypertension in Japan Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Microvascular coronary perfusion and hyperinflation in COPD – data from the LEAD (Lung, hEart, sociAl, boDy) study Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms Year: 2018 Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Variation in mortality from pulmonary hypertension by aetiology Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Lung transplantation for pulmonary arterial hypertension Source: International Congress 2015 – Lung transplantation in the year 2015: current indications and results Year: 2015 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Myocardial perfusion in patients with pulmonary hypertension of different etiology Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Small airways dysfunction in chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Dyspnoea and respiratory muscle mechanics dysfunction in disease Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Epidemiology of pulmonary hypertension. Preliminary results of the Spanish pulmonary hypertension registry Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017 Longitudinal change in non-invasive markers in interstitial lung disease associated pulmonary hypertension and correlation with invasive pulmonary haemodynamics Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Randomized, controlled, prospective multicenter study: Training improves peak oxygen consumption and hemodynamics in patients with chronic severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Hemodynamic assessment of patients with pulmonary hypertension due to lung disease and/or hypoxia Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013